Culture, Biotech Jessica Sagers Culture, Biotech Jessica Sagers

Is ChatGPT smarter than Congress?

We asked ChatGPT some of the most common questions with which we see our elected representatives struggle. Does NIH invent drugs? What are profit margins like in the pharmaceutical industry? Will lowering drug list prices via imposing price controls on pharmaceutical companies lower patients' out-of-pocket costs? Find out what AI thinks.

Read More
Policy, Finance, Biotech Chris Morrison Policy, Finance, Biotech Chris Morrison

Alnylam is doing what the IRA is telling it to do

The recent announcement by Alnylam Pharmaceuticals that it was holding off on a planned Phase 3 pivotal study for vutrisiran (marketed as Amvuttra in its sole approved indication so far, hATTR amyloidosis with polyneuropathy) in Stargardt disease illustrates how the Inflation Reduction Act is already having a negative impact on small molecule and orphan drug R&D prioritization. Alnylam’s announcement also brought out skeptics of the biotech industry, who argue the new law is being scapegoated by innovators who want to overturn its Medicare drug-negotiation provisions.

Read More
Policy, Biotech Chris Morrison Policy, Biotech Chris Morrison

Navigating a storm that threatens American biotechnology

Over the past four decades, David Beier has observed and participated in the evolution of the US biotechnology industry for several key vantage points. The industry’s success and freedom to innovate, he says, has been underpinned by – and helped create – a marketplace that was open enough to fully reward risk-taking investors devoting capital to cutting edge science. Today, that success faces new threats.

Read More